Caris Life Sciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered undervalued, ranking 65/208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 38.11.In the medium term, the stock price is expected to remain stable.The company has been performing strongly in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Caris Life Sciences Inc's Score
Industry at a Glance
Industry Ranking
65 / 208
Overall Ranking
162 / 4582
Industry
Healthcare Equipment & Supplies
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
9
analysts
Buy
Current Rating
38.111
Target Price
+34.38%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Caris Life Sciences Inc Highlights
StrengthsRisks
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Undervalued
The company’s latest PE is -5.53, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 130.04M shares, increasing 49.48% quarter-over-quarter.
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
Ticker SymbolCAI
CompanyCaris Life Sciences Inc
CEOHalbert (David Dean)
Websitehttps://www.carislifesciences.com/
FAQs
What is the current price of Caris Life Sciences Inc (CAI)?
The current price of Caris Life Sciences Inc (CAI) is 27.940.
What is the symbol of Caris Life Sciences Inc?
The ticker symbol of Caris Life Sciences Inc is CAI.
What is the 52-week high of Caris Life Sciences Inc?
The 52-week high of Caris Life Sciences Inc is 42.500.
What is the 52-week low of Caris Life Sciences Inc?
The 52-week low of Caris Life Sciences Inc is 22.860.
What is the market capitalization of Caris Life Sciences Inc?
The market capitalization of Caris Life Sciences Inc is 7.88B.
What is the net income of Caris Life Sciences Inc?
The net income of Caris Life Sciences Inc is -378.26M.
Is Caris Life Sciences Inc (CAI) currently rated as Buy, Hold, or Sell?
According to analysts, Caris Life Sciences Inc (CAI) has an overall rating of Buy, with a price target of 38.111.
What is the Earnings Per Share (EPS TTM) of Caris Life Sciences Inc (CAI)?
The Earnings Per Share (EPS TTM) of Caris Life Sciences Inc (CAI) is -5.049.